gvtcx

Atazanavir / Cobicistat (Evotaz®)

The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Statuscomplete
Category (CPV) 33600000
RegionScotland
Procedurelimited
OCIDocds-h6vhtk-0313b1

Award

SupplierValueDateStatus
Bristol-Myers Squibb Pharmaceuticals · · active

description

Supply of Atazanavir 300mg / Cobicistat 150mg tablets (Evotaz®) to NHS Scotland.

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

2 notices published against this procurement.

PublishedTypeRegimeNotice
7 Feb 2022 Voluntary ex-ante transparency (F15) Earlier regulations 003350-2022
14 Mar 2022 Contract award notice (F03) Earlier regulations 006854-2022

more from The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Public Contracts Scotland. Contact details for named individuals are not reproduced on this site.